司美格鲁肽停药后体重反弹？因为你没有这样做

Core Viewpoint - The article discusses the rising obesity rates in China and the impact of GLP-1 medications, particularly semaglutide, on weight loss and the challenges faced by users in maintaining medication adherence [4][6][16]. Group 1: Obesity Statistics and Economic Impact - China has the highest number of overweight and obese individuals globally, with over 50% of the adult population affected, totaling approximately 532 million, including nearly 100 million classified as obese [4]. - By 2030, it is projected that the number of overweight adults in China will reach 540 million, and the obese population will increase to 150 million, representing a 2.8-fold and 7.5-fold increase from 2000, respectively [4]. - The global obesity rate is expected to rise to 25% by 2035, up from 14% in 2020, with obesity impacting personal health and causing an estimated economic loss equivalent to 3.6% of the U.S. GDP, potentially costing up to $1.24 trillion in indirect costs [4]. Group 2: Medication Adherence and Efficacy - A study published in the journal "Obesity" indicates that semaglutide has the highest adherence rate among weight loss medications, with 63% of users still on the medication after three months, 56% after six months, and 40% after one year [6]. - In a clinical trial, participants using semaglutide lost an average of 10.6% of their body weight over 20 weeks, but those who switched to a placebo regained an average of 6.9% of their weight, while those who continued with semaglutide lost an additional 7.9% [7]. Group 3: Reasons for Discontinuation - Common side effects of GLP-1 medications include nausea, diarrhea, vomiting, constipation, abdominal pain, and gastroesophageal reflux, with 17% of patients reporting nausea even at low doses [8]. - Supply issues have also been a challenge since 2022, leading to difficulties in accessing semaglutide [8]. - Patients may stop using the medication due to reaching their target weight, experiencing a plateau in weight loss, or the medication not being covered by insurance, requiring out-of-pocket expenses [9]. Group 4: Recommendations for Discontinuation and Lifestyle Maintenance - It is recommended to gradually reduce the dosage of GLP-1 medications rather than stopping abruptly to mitigate increased hunger sensations [10][12]. - Maintaining a healthy diet and regular exercise is crucial for preventing weight regain after discontinuation of medication [13][15]. - Continuous use of semaglutide is emphasized as obesity is a chronic condition requiring long-term management, similar to other chronic diseases [16].